Acquisition Alignment Telix's acquisition creates an avenue to secure ongoing licensing and potential co-development of ImaginAb's CD8 ImmunoPET imaging asset across Telix's oncology programs and global footprint.

Licensing Expansion CD8 ImmunoPET is licensed by multiple pharma and biotech sponsors; identify opportunities to expand with existing licensees and cross-sell additional imaging platforms and minibody technologies to new immuno-oncology partners.

CRO Collaboration Leverage established CRO partnerships to deepen preclinical radiopharmaceutical work and offer end-to-end services from discovery through imaging validation and IND-enabling studies.

Theranostics Opportunity Pipeline opportunities in radiopharmaceutical therapy enable potential collaborations with developers and treatment centers to combine diagnostic imaging with therapy programs.

Strategic Targeting With a lean team and global oncology focus, target a select set of strategic pharma and biotech partners seeking imaging biomarkers for immunotherapy trials, highlighting fast access to proprietary minibody platforms.